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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is one of the most devastating neurodegenerative diseases.
Neurotrophic factors have been widely tested to counteract neurodegenerative conditions, despite their unspecific
neuronal access. The non-toxic C-terminal fragment of the tetanus toxin (TTC) heavy chain has been studied not
only as a carrier molecule to the CNS but also as a neuroprotective agent. Because the neurotrophic effects of
BDNF have been demonstrated in vitro and in vivo, the question addressed in this work is whether a fusion
molecule of BDNF-TTC may have a synergistic effect and enhance the neuroprotective properties of TTC alone in a
mouse model of ALS.
Methods: Recombinant plasmid constructs (pCMV-TTC and pCMV-BDNF-TTC) were injected into the quadriceps
femoris and triceps brachialis muscles of SOD1G93A transgenic mice at 8 weeks of age. The hanging wire and
rotarod tests were performed to assess motor coordination, strength and balance. Electrophysiological tests,
morphological assays of spinal cord sections of L2 and L4 segments, and gene and protein expression analyses
were performed. The Kaplan-Meier survival analysis test was used for comparisons of survival. Multiple comparisons
of data were analyzed using a one-way analysis of variance (ANOVA).
Results: Treatment with the fusion-molecule BDNF-TTC and with TTC alone significantly delayed the onset of
symptoms and functional deficits of SOD1G93A mice. Muscle innervation was partially preserved with these
treatments, and the number of surviving motoneurons in L2 spinal cord segment was increased particularly by the
fusion protein induction. Inhibition of pro-apoptotic protein targets (caspase-3 and Bax) and significant
phosphorylation of Akt and ERK were also found in the spinal cord of treated mice.
Conclusions: Significant improvements in behavioral and electrophysiological results, motoneuron survival and anti-
apoptotic/survival-activated pathways were observed with BDNF-TTC treatment. However, no synergistic effect was
found for this fusion molecule. Although BDNF in the fusion molecule is capable of activating autocrine and
neuroprotective pathways, TTC treatment alone yielded similar neuroprotection. Therefore, an accurate study of the
neuroprotective effects of TTC fusion molecules should be performed to obtain a better understanding of its effects.
Background
Amyotrophic lateral sclerosis (ALS) is one of the most
devastating neurodegenerative diseases, involving the
progressive loss of motoneurons, muscle weakness and
atrophy. ALS occurs in 4 to 8 of every 100,000 indivi-
duals worldwide [1] and 10% of the affected people have
an inherited genetic component [2]. Susceptibility to
familial ALS (FALS) is associated with mutations in var-
ious genes, the most frequent being mutations in the
superoxide dismutase-1 (SOD1) gene [3]. Transgenic
mice over-expressing human SOD1 with a G93A muta-
tion (SOD1G93A) are one of the best characterized
experimental ALS models [4] and many preclinical trials
have been conducted in these mice to test a wide range
of potential therapeutic molecules [5].
The search for an efficient treatment that prevents
motoneuronal death could be especially useful in ALS.
The retrograde and trans-synaptic transport of the
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C-fragment of the tetanus toxin (TTC) into the central
nervous system (CNS) after an intramuscular injection
of naked DNA or recombinant protein has been widely
demonstrated and was originally used for the transport
of active molecules because of the carrier properties of
TTC [6-8].
Interestingly, recent evidence has raised the potential
use of the TTC heavy chain as a therapeutic agent for
neurodegeneration. In vitro studies have reported that
TTC rescues degenerating cultured neurons from apop-
totic death through the activation of phosphatidylinosi-
tol 3-kinase (PI3K) and mitogen-activated protein kinase
(MAPK) survival signaling pathways [9]. Furthermore,
our group has recently described that the intramuscular
gene delivery of TTC in SOD1G93A mice exerts a posi-
tive effect on the prevention of neurodegeneration,
improves motor function, inhibits apoptotic pathways
and prolongs the survival of these animals [10].
The fusion of TTC and an active molecule, such as a
trophic factor, could strengthen the neuroprotective
properties of TTC. The combination of TTC- and glial-
derived neurotrophic factor (GDNF) has been evaluated
in a neonatal rat axotomy model [11] and in the ALS
mouse model [12]. The combination of TTC with insu-
lin growth factor (IGF-1) has also been assayed in trans-
genic SOD1G93A mice [13], although the effect of TTC
alone has not been compared in any of these studies.
When the effect of TTC was compared to the fusion
molecule in vitro, a significant increase in the survival
capacity of neuronal cells was found [12]. However
in vivo, no significant differences were observed, which
is probably due to the possibility that the fusion mole-
cule might follow a GDNF route and not the TTC route
under axotomy conditions [11].
A previous study reported that some neurotrophic fac-
tors, in particular brain derived neurotrophic factor
(BDNF), facilitate the internalization of TTC fusion
molecules in motor nerve terminals [14]. We have also
observed that TTC and the recombinant fusion protein
BDNF-TTC inhibit apoptosis in cultured neurons, with
the quimeric molecule being more effective than TTC
alone [9]. BDNF may cause a relocalization of mem-
brane domains containing TTC receptors by activating
Trk receptors, thereby facilitating the neuronal internali-
zation of TTC. This observation is supported by other
authors who state that TTC activates intracellular path-
ways involving Trk receptors [15]. BDNF belongs to the
family of neurotrophins and binds specifically to TrkB
receptors to activate the intracellular signaling pathways
that promote neuronal survival and the differentiation of
neurons. The neurotrophic effects of BDNF on moto-
neuronal degeneration have been widely studied in vitro
and in vivo [16,17]. This neurotrophin has also been
proposed as a potential therapeutic agent for the
treatment of human ALS [18], although no successful
results have been achieved. This failure in the clinical
application of BDNF may be due to the low efficacy of
targeting the neurotrophic factor to motoneurons. TTC
possesses a high affinity for motoneurons [6], and the
fusion of BDNF to the TTC protein might increase its
accessibility. Taking all of these observations together,
we speculated that the fusion of BDNF to TTC might
have a synergistic positive effect. In the present study,
we treated transgenic SOD1G93A mice intramuscularly
with a plasmid encoding for the fusion protein BDNF-
TTC and investigated whether the beneficial effects of
TTC previously observed on SOD1G93A mice were
enhanced by the presence of BDNF.
Methods
Construction of recombinant plasmids carrying TTC and
BDNF-TTC DNA
Site-directed mutagenesis was used to introduce restric-
tion sites of interest in the 5’/3’ ends and/or to eliminate
stop sequences to finally obtain the recombinant plas-
mids. The amplified sequences of TTC and BDNF were
purified (QIAquick PCR purification kit, QIAGEN) and
used as templates for cloning, using the PMOSBlue vec-
tor (Amersham Biosciences, GE Healthcare Europe
GmbH, Barcelona, Spain), before being inserted in the
eukaryotic expression plasmid. All potential therapeutic
genes used in mice treatments were constructed in the
pcDNA3.1 (Invitrogen S.A., Prat de Llobregat, Spain)
eurkaryotic expression plasmid under the control of the
cytomegalovirus (CMV) immediate-early promoter.
pCMV:TTC was obtained by cloning a BamHI/NotI
TTC fragment from the pGex:TTC vector [6] into
pcDNA3.1. For pCMV:BDNF-TTC construction, the
mature form of BDNF was obtained from a pcDNA3:
BDNF vector (a gift from Dr. Pérez-Mediavilla, Univer-
sity of Navarra, Spain). PCR was used to eliminate the
BDNF stop codon and to introduce HindIII (5’-end) and
BamHI (3’-end) restriction sites for subcloning in the
pMOSBlue vector. The HindIII/BamHI BDNF fragment
was then introduced in pCMV:TTC to generate pCMV:
BDNF-TTC (Figure 1). For the transformation assay,
competent cells (E. Coli DH5a bacteria) were used, and
the constructed plasmids were purified with QIAprep
Spin Miniprep kit (QIAGEN). The sequence of the puri-
fied plasmids (BigDye Terminator v3.1 Cycle Sequencing
kit, Applied Biosystems) was checked to confirm that
the cloned DNA fragments were correctly inserted in
the respective vectors. The recombinant plasmids were
finally expanded in E. Coli DH5a bacteria and purified
using the GenElute Endotoxin-free Maxiprep Plasmid
Purification Kit (Sigma). This kit was suitable for gene
therapy treatments due to its capacity to eliminate bac-
terial endotoxins during the plasmid extraction process.
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The recombinant plasmids were subjected to 1% agarose
gel in 1X Tris-boric-EDTA (TBE) to yield fragments of
the expected molecular weight. The quantity of the
obtained recombinant plasmids was measured using a
NanoDrop® Spectrophotometer, ND-1000 V3.3.0, and
plasmid concentration was adjusted to 1 μg/μl in a PBS
solution.
Transgenic mice
Transgenic mice with the G93A human SOD1 mutation
(B6SJL-Tg[SOD1-G93A]1Gur) were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). The
colony was maintained by breeding male transgenic ani-
mals to naive (B6SJL) F1 females obtained from Charles
River Laboratories (Belgium). All efforts were taken to
minimize pain and discomfort and to maintain stable
light/dark cycles.
The offspring were identified by PCR amplification of
DNA extracted from tail tissue as described in the Jack-
son Laboratory protocol for the genotyping of hSOD1
transgenic mice http://jaxmice.jax.org/protocolsdb/f?
p=116:2:351753648875652::NO:2:P2_MASTE R_PRO-
TOCOL_ID,P2_JRS_CODE:523,002726 (based on [3]).
Non-transgenic (wild-type) littermates were used as
negative controls for the genetic background, and
SOD1G93A transgenic mice injected with empty plasmids
were used as positive controls. Following the standard
considerations for preclinical studies using SOD1 mice
[19,20], all of the experimental designs were blinded and
included the recommended number of animals. Equal
numbers of balanced littermate males and females were
assigned to the specific treatment groups.
Mice were housed in the Unidad Mixta de Investiga-
ción of the University of Zaragoza. Food and water were
available ad libitum. All experimental procedures were
approved by the Ethics Committees of our institutions
and followed the guidelines for the use of laboratory
animals based on the NIH Guide for Care and Use of
Laboratory Animals (1985) and the European Commu-
nities Council Directive (86/609/EEC).
In vivo intramuscular injections
Intramuscular injections of naked DNA encoding for
pCMV-TTC, -BDNF, -BDNF-TTC and non-coding
pCMV plasmids (50 μl, 1 μg/μl) were administered into
the quadriceps femoris and the triceps brachialis mus-
cles of balanced male and female SOD1G93A transgenic
mice at 8 weeks of age. Each quadriceps muscle was
injected with 100 μg of plasmid in two injections,
whereas each triceps muscle was given one injection
with 50 μg of plasmid using an insulin syringe (25GA 5/
8 Becton Dickinson SA, Madrid, Spain) following
Figure 1 Construction of pcDNA3.1-TTC and pcDNA3.1-BDNF-TTC recombinant plasmids. A. Restriction maps of the recombinant plasmids
pcDNA3.1-TTC and pcDNA3.1-BDNF-TTC. B. Primers used to amplify the sequences of TTC and of the mature form of BDNF were inserted in the
recombinant plasmids of 6824 and 7175 base pairs, respectively.
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the guidelines for preclinical animal research [19,20].
A positive control group of SOD1G93A transgenic mice
was similarly injected with the same amount of empty
plasmid.
For the PCR amplification for the detection of TTC
expression in quadriceps extracts after the intramuscular
injections of TTC and BDNF-TTC plasmids, the control
positive group (i.e., the SOD1G93A transgenic mice
injected with empty plasmids) was used to test TTC
expression in skeletal muscle. The negative control
group (age-matched wild-type animals) was not injected
with any of the recombinant plasmids. However, in rela-
tion to the western blot detection of TTC in spinal cord
and skeletal muscle tissues, the negative control group
and the positive control group were used to confirm
that the detected bands corresponded to the recombi-
nant protein but not to a technical error.
Behavioral and functional evaluations
At two months of age, balanced males and females
SOD1G93A mice were blindly treated with the recombi-
nant plasmids pCMVTTC, pCMV-BDNF, pCMV-
BDNF-TTC or pCMV empty plasmid (positive control
group) for behavioral analyses following the guidelines
for preclinical animal research [19,20]. The control
group, SOD1G93A transgenic mice injected with empty
plasmids, was used in this study to analyze the effect of
naked DNA treatment during disease progression in
ALS SOD1G93A transgenic mice.
The onset of symptoms was evaluated using the
rotarod test, which assesses muscle strength, motor
coordination and balance [21,22]. All animals performed
this test weekly beginning on the treatment day and fol-
lowed the same methodology previously established in
this animal model [21] according to the guidelines for
preclinical animal research [19]. The hanging wire test
was used to assess muscle strength. Each mouse was
placed on the wire lid of a conventional housing cage.
The lid was gently turned upside down 60-cm above a
soft surface to avoid injuries. The latency to fall was
timed. Each mouse was given up to three attempts to
hold on to the inverted lid for a maximum of 180 s, and
the longest period was recorded.
One week before the injections, the mice were trained
daily on a Rotarod apparatus (ROTAROD/RS, LE8200,
LSI-LETICA Scientific Instruments; Panlab S.L., Barce-
lona, Spain). After injections, SOD1 mutant mice were
tested weekly for their ability to maintain their balance
on the Rotarod apparatus at a constant speed of
15 rpm. The time an animal could remain on the rotat-
ing rod out of a maximum of 180 s was measured. The
animals were tested three times during each session,
and the best performance was recorded. Weight data
were also recorded weekly from 8 weeks of age. Mice
were sacrificed when they were unable to right them-
selves within 30 s after being placed on their side; this
point was considered as the survival endpoint according
to the guidelines for preclinical testing and colony man-
agement [19,20]. The weekly blinded monitoring for dis-
ease onset, disease progression and the end stage was in
accordance to the guidelines for preclinical animal
research [19], with the optimized method described in a
previous work [21] and with similar studies in the same
animal model [23]. The Kaplan-Meier test was used to
analyze disease onset and life span.
Electrophysiological tests and histological processing
Electrophysiological tests were performed at 3 and 4
months of age in other subgroups of SOD1G93A treated
as above, including negative (age-matched wild-type)
and positive control (SOD1G93A mice injected with
empty plasmid) groups. Motor nerve conduction was
evaluated by stimulating the sciatic nerve at the sciatic
notch and recording the compound muscle action
potentials (CMAP) from the gastrocnemius and plantar
muscles with microneedle electrodes [24]. The evoked
potentials were amplified and displayed on a digital
oscilloscope to measure the amplitude from the baseline
to the maximal negative peak and the latency from the
stimulus to the onset of the first negative deflection.
During electrophysiological tests, the animals were
anesthetized (pentobarbital 40 mg/kg i.p.) and placed
over a warm flat steamer to maintain body temperature
that was monitored with a skin thermode. Following
electrophysiological tests, the anesthetized animals were
perfused with 4% paraformaldehyde in PBS at 4 months
of age. The lumbar segment of the spinal cord was
removed, post-fixed and cryopreserved in 30% sucrose.
Transverse 40- μm-thick sections were serially cut using
a cryotome. One section from each series of 10 sections
was collected sequentially on gelatin-coated slides and
stained with cresyl violet. The number of motoneurons
present in both ventral horns was counted in four serial
sections of each L2 and L4 spinal cord segments in all
treated groups, and the negative and positive controls.
Motoneurons were identified by their localization in the
ventral horn and counted following strict size and mor-
phological criteria [10,25]. The number of motoneurons
in the treated groups was compared to the number of
motoneurons in the negative (wild type) and positive
(SOD1G93A) controls to study motoneuron survival
under each treatment.
Other spinal cord sections of the L2 segment were
blocked with TBS-Triton-FDS and incubated for 2 days at
4°C with primary antibody anti-BDNF (1:10000, Millipore)
or anti-TTC (1:500, antibody SP48 purified in rabbit,
Eurogentec, Belgium). After washes, sections were incu-
bated for 1 day at 4°C with biotinilated secondary antibody
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(1:200; Vector) or with anti-rabbit Cy3-conjugated anti-
body (1:200, Jackson Immunoresearch). Finally,
when necessary, they were incubated for 1 h with Cy3-
conjugated streptavidin (1:1000, Zymed). Microphoto-
graphs of the grey matter of the ventral horn were taken
at 200× and 400× to determine the immunolabeling of
BDNF or TTC.
Extraction of biological samples
Biological samples were extracted from SOD1G93A trans-
genic mice and age-matched wild-type mice (negative
control) that were anesthetized with a sodium pentobar-
bital solution (50 mg/kg i.p.) to extract the tissue samples
as quickly as possible [26,27]. For the detection of
injected plasmid expression, inoculated muscles were
harvested 10 days after plasmid injections. Another
group of naked DNA-treated (empty plasmid) SOD1G93A
transgenic mice (positive control) was sacrificed 50 days
post-injections, and spinal cord tissues were harvested
for gene expression and western blot analyses. Spinal
cord tissue from non-transgenic age-matched mice was
also extracted as negative controls for the genetic
background.
RNA extraction, synthesis of cDNA and PCR amplification
from biological samples
Tissues were frozen in liquid nitrogen and stored at
-70°C for subsequent RNA and protein extraction. For
total RNA extraction, tissues were pulverized in a cold
mortar using liquid nitrogen and homogenized with a
pro200 homogenizer (PRO Scientific Inc., Oxford, CT,
USA). TRIzol Reagent (Invitrogen S.A., Prat de Llobre-
gat, Spain) was used for total RNA extraction from mus-
cles according to the manufacturer’s instructions. Spinal
cord homogenized tissue from treated and positive
(empty plasmid) control SOD1G93A transgenic and wild-
type mice was transferred to two pre-chilled tubes, one
for total RNA extraction (RNeasy Mini Kit protocol,
Qiagen-Izasa, Barcelona, Spain) and the other for pro-
tein extraction. RNA was treated to eliminate genomic
DNA using Turbo DNA-free (Ambion, Madrid, Spain).
For retrotranscription (RT), the SuperScriptTM First-
Strand Synthesis System kit (Invitrogen S.A., Prat de
Llobregat, Spain) was used for 1 μg of RNA in a final
volume of 20 μl.
Intramuscular plasmid transfection and expression was
detected with primers for TTC amplification in injected
muscles. cDNA amplification reactions were performed in
a final volume of 10 μl containing 300 nM of each primer
(forward, 5’-ATGGAAGCAGTAAAATTGCGTGA-3’ and
reverse, 5’-TTGCCTATTTGACCATTATGGGTA-3’),
5 μl of 2X SYBR® Green PCR Master Mix (Applied Bio-
systems, Madrid, Spain) and 2 μl per reaction of 10×
diluted cDNA for the detection of the TTC gene expres-
sion in muscle samples. All PCR reactions were performed
using an ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Madrid, Spain). The thermal cycling
parameters were as follows: incubation at 95°C for 10 min-
utes and 40 cycles of 95°C for 15 seconds and 60°C for 1
minute. The presence of the TTC gene amplicon (115 bp)
was also observed in a 4% agarose gel stained with ethi-
dium bromide.
Real-time PCR was used to study gene expression in
the spinal cord from treated SOD1G93A transgenic mice.
The gene expression values were compared to the values
obtained in the positive control group, whereas the
negative control group was used as a reference to a
non-pathologic situation. Reactions were performed in a
final volume of 10 μl with a 1× TaqMan® Universal
PCR Master Mix (No AmpErase® UNG, Applied Biosys-
tems, Madrid, Spain), 1× of the primer and TaqMan®
MGB probe mix for each studied gene and 1 μl of a 10×
-diluted cDNA per reaction. For normalization, 3 endo-
genous genes were used (18 S rRNA, GAPDH and b-
actin). All reactions were performed in triplicate; the
efficiency of the primer/probe sets was close to 100% in
all reactions. Primer and probe mixtures for the genes
of interest were supplied by Applied Biosystems
(Madrid, Spain) (Table 1). PCR reactions were per-
formed in an ABI Prism 7000 Sequence Detection Sys-
tem (Applied Biosystems, Madrid, Spain). The thermal
cycling parameters were as follows: incubation at 95°C
for 10 minutes, 40 cycles of and 95°C for 15 seconds
and 60°C for 1 minute. The relative expressions of
Gabra4 were normalized with the geometric mean of
the three endogenous genes [28].
Table 1 Taqman® probe and primer mixtures used in gene expression assays
NAME GENE SYMBOL SEQUENCE PROBE LOCATION ORGANISM PART NUMBER
gamma-aminobutyric acid (GABA-A) receptor GABRA4 NM_010251.2 Exon 8-9 Mus musculus Mm00802631_m1
subunit alpha 4
glyceraldehyde-3-phosphate dehydrogenase GAPDH NM_008084.2 Exon 3 Mus musculus 4352932E
actin, beta, cytoplasmic ACTB (b-actin) NM_007393.1 Exon 6 Mus musculus 4352933E
18 S ribosomal RNA 18 S rRNA X03205.1 Homo sapiens Hs99999901_s1
GAPDH, b-actin and 18 S rRNA were used as housekeeping genes. Gabra4 was selected as a target gene to study GABAergic transmission under TTC, BDNF and
BDNF-TTC treatments.
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Protein extraction and Western blot analysis
Powdered spinal cord tissue for protein extraction was
resuspended in homogenization buffer [15,29,30] con-
taining 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1%
deoxycholate, 0.1% SDS, 1% Triton X-100, 1 mM
Na3VO4 (a phosphatase inhibitor) together with the
complete protease inhibitor cocktail 1 mM PMSF, 10
μg/ml leupeptin/aprotinin and 1 μg/ml pepstatin, and
centrifuged for 10 min at 4°C at 3000 rpm. The super-
natant was collected, and the protein concentration was
quantified by BCA (Sigma-Aldrich Química, S.A.,
Madrid, Spain). Protein extracts (25 μg of total protein)
were subjected to SDS/PAGE and transferred to PVDF
membranes (Amersham Biosciences, GE Healthcare
Europe GmbH, Barcelona, Spain) using a Mini Protean
3 (Bio-Rad, Hercules, CA, U.S.A.) at 100 V for 1 h. The
blotting buffer used contained 25 mM Tris, 200 mM
glycine and 10% (v/v) methanol. PVDF membranes were
blocked for 1 h with Tris-buffered saline supplemented
with 0.1% Tween 20 and 5% (w/v) skimmed powdered
milk. The membranes were incubated overnight with
the corresponding primary antibody diluted in blocking
buffer: 1:500 anti-TTC, 50 KDa (antibody SP48 purified
in rabbit, Eurogentec S.A., Belgium), 1:1000 Procaspase-
3, 35 KDa (9662), 1:1000 p44/42 MAPK, 44/42 KDa
(4348), 1:1000 phospho-p44/42 MAPK, 44/42 KDa
(9106) (Cell Signaling Technology, Inc., Danvers, MA,
USA); 1:200 Caspase-3, 11 KDa (AM65) (Calbiochem,
San Diego, CA, USA); 1:1000 BDNF, ~ 20 KDa (sc-546),
1:2000 Bax, 23 KDa (sc-526), 1:2000 Bcl-2, 29 KDa
(sc-492), 1:1000 total Akt, 60 KDa (sc-8312), 1:1000
phospho-Akt, 60 KDa (sc-7985-R), 1:5000 b-tubulin
antibody, 55 KDa (sc-9104) (Santa Cruz Biotechnology,
Inc., CA, USA). Several washes were performed with
Tris-buffered saline/0.1% Tween 20 between each step.
The secondary antibody was diluted 1:5000 in blocking
buffer (goat anti-rabbit IgG-HRP or goat anti-mouse
IgG-HRP, Santa Cruz Biotechnology, Inc.). The western
blots were developed using Western Blotting Luminol
Reagent (Santa Cruz Biotechnology, Inc., California
95060) and exposed to Agfa X-Ray films (Agfa, 2640
Mortsel, Belgium). The computer-assisted analysis of the
bands was performed with AlphaEase FC software (Bon-
sai Technologies Group, S.A., Madrid, Spain). All the
protein levels were tested in treated SOD1G93A trans-
genic mice and compared to the positive (empty plas-
mid) control group and the levels observed in the
negative control group, which served as a reference to a
non-pathologic situation.
Statistical analysis
All values are expressed as the mean ± S.E.M., and the n
= number of mice in each group. Regarding the statisti-
cal analysis of the clinical outcomes, the Kaplan-Meier
analysis was used for survival comparisons using a log-
rank test to establish the efficacy of each treatment with
a statistical significance set at a P value < 0.05. Multiple
comparisons of data were analyzed using a one-way ana-
lysis of variance (ANOVA) followed by a Bonferroni
post-hoc test. Variance in disease onset was analyzed
using a one-way ANOVA followed by a Fisher’s least
significant difference (LSD) post-hoc test. Variances in
motor function, strength and weight score curves were
analyzed using a repeated measures ANOVA followed
by Fisher’s LSD testing. For gene expression and wes-
tern blot data analysis, a one-way ANOVA was used fol-
lowed by a Tukey post-hoc test. Statistical differences
were considered significant at P < 0.05 level.
Results
Detection of TTC expression in the muscle and spinal
cord of transfected SOD1G93A mice
We first confirmed the ability of the constructed vector
to express the encoding gene within the muscle cells of
SOD1G93A transgenic mice. Because there is no endogen-
ous expression of the TTC gene in the skeletal muscle of
mice, PCR amplification of cDNA of the injected muscles
was performed to detect mRNA expression of the gene.
Previous studies on the spatial-temporal patterns of gene
expression in mouse skeletal muscle after the injection of
plasmid-DNA have revealed maximal expression levels
between 7 and 14 days after injection [31]. The quadri-
ceps muscles extracted from transgenic mice were used
for the study of the expression of the plasmid constructs
(pCMV-TTC and pCMV-BDNF-TTC) or empty plasmid
10 days after inoculation. As shown in Figure 2A, TTC
gene expression was not observed in the control
SOD1G93A group (empty naked DNA-injected transgenic
mice). In contrast, RT-PCR revealed the presence of the
TTC gene amplification in muscles inoculated with the
TTC and BDNF-TTC encoding vectors, indicating that
they were transcribed in the muscle cells. Furthermore,
to confirm that the TTC was transported to the spinal
cord, a Western blot for TTC and BDNF proteins was
performed. TTC and BDNF protein expression was only
observed in the skeletal muscle and the spinal cord of
TTC and BDNF-TTC-treated mice. BDNF was also
detected in BDNF-treated mice. Conversely, neither TTC
nor BDNF detection was found in wild-type and control
SOD1G93A mice (empty naked DNA-injected transgenic
mice) (Figure 2B).
Transport efficiency mediated by TTC
The efficiency of the transport of BDNF mediated by
TTC was also detected immunohistochemically. The
immunohistochemical labeling demonstrated positive
BDNF and TTC immunoreactivity only in the soma of
spinal motoneurons of mice treated with BDNF-TTC;
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spinal motoneurons of mice treated with BDNF did not
show any labeling (Figure 3A). To confirm the long-
term stability of the BDNF molecule, GABA(A) receptor
gene expression was tested in the spinal cord samples of
wild-type mice (negative control), positive control
SOD1G93A mice and BDNF-, BDNF-TTC- and TTC-
treated mice. Real-time PCR was conducted on cDNAs
obtained from total spinal cord extracts to examine
whether treatment with the different plasmid constructs
could affect GABA(A) receptor expression (subunit 4,
Gabra4). In agreement with previous studies, our results
showed a significant down-regulation of Gabra4 levels
in BDNF-TTC- and BDNF-treated mice. However, TTC
treatment did not affect the expression pattern of
Gabra4 in the transgenic mice. Interestingly, a signifi-
cant up-regulation of Gabra4 expression in the spinal
cord of control SOD1G93A mice was found compared to
the wild-type age-matched animals (Figure 3B).
Naked -DNA TTC and BDNF-TTC treatment improve
disease clinical outcomes in SOD1G93A mice
Due to the fact that the first signs of motor deficits in
transgenic SOD1G93A mice are usually detected near 100
days of age, naked DNA (TTC, BDNF-TTC and BDNF)
treatment was administered at 8 weeks, which is well
before the disease onset. The disease onset was mainly
evaluated using the rotarod test. The intramuscular
injection of pCMV-TTC or -BDNF-TTC plasmids
delayed disease onset and improved motor function of
SOD1G93A treated mice compared to the positive con-
trol group. However, these improvements were not
observed when pCMV-BDNF was injected (Figure 4).
Figure 2 TTC and BDNF detection in skeletal muscle and spinal cord of ALS transgenic SOD1G93A mice. A. PCR amplification for the
detection of TTC expression in mouse quadriceps extracts after intramuscular injections of TTC and BDNF-TTC plasmids. (1) TTC plasmid injected
quadriceps extract; (2) BDNF-TTC-plasmid injected quadriceps extract; (3) molecular weight marker, MW; (4) positive control, C (vehicle or empty-
plasmid-injected quadriceps extract); (5) reaction blank (n = 5 mice per group). B. Western blot detection of TTC in spinal cord and skeletal
muscle tissues of wild-type (C-, negative control), SOD1G93A transgenic mice injected with empty plasmid (C+, positive control), TTC- and BDNF-
TTC (BTTC)-treated mice. In TTC and BDNF-TTC treated groups, the detected band was approximately of 50 and ~ 70 KDa respectively (*), using
both anti-TTC and anti-BDNF antibodies. In the BDNF group, the dimeric conformation, indicated by arrows, was observed at approximately 40
KDa (n = 5 mice per group).
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Figure 3 Transport efficiency of BDNF-TTC molecule. A. Immunohistochemical labeling for BDNF expression in the grey matter of the ventral
horn of of (a) positive control (SOD1G93A transgenic mice injected with empty plasmid), (b) SOD1G93A-BDNF and (c) L2 and (d) L4 spinal
segments of SOD1G93A-BDNF-TTC mice. Note that BDNF is only expressed in the L2 spinal cord sections of mice treated with BDNF-TTC chimera
and does not appear in other spinal cord segments. (e, f) Detail of BDNF immunolabeling of the sections shown in c and d, at higher
magnification. Presence of TTC in the grey matter of the ventral horn of (g) SOD1G93A-BDNF-TTC and (h) SOD1G93A-TTC treated mice. Note more
intense TTC labeling in animals treated with the chimera. Arrows point to some of the neurons positively stained for TTC. Bar = 200 μm in a, b,
c, d, g and h; bar = 100 μm in e and f. B. Real-time PCR assay of a synaptic transmission-related gene in spinal cord specimens of symptomatic
SOD1G93A mice. Fold-changes in the expression of GABA(A) receptor subunit-4 (Gabra4) mRNA levels in total spinal cord of wild-type (negative
control), positive control and treated transgenic mice. Results showed a significant down-regulation of the expression of this gene in
neurotrophin-bearing treatments (BDNF-TTC and BDNF), approaching wild-type levels (*P < 0.05, **P < 0.01; error bars indicate SEM).
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Significant differences in the TTC- and BDNF-TTC-
treated groups (118.7 ± 1.9 and 125.3 ± 3.3 days, respec-
tively) were found compared to the control group
(97.1 ± 4.7 days) but not for BDNF-treated animals
(105.6 ± 3.2 days) regarding the onset of the sympto-
matic phase (Figures 4A-C).
Regarding the life span, mice treated with naked DNA
TTC (136.0 ± 3.2 days, log-rank test, p = 0.013) and
with BDNF-TTC (139.2 ± 2.6 days, log-rank test, p =
0.001), but not mice treated with BDNF (131.8 ±
3.1 days, log-rank test, p = 0.175), showed significantly
longer survival rates compared to the positive control
SOD1G93A mice (121.3 ± 3.6 days) (Figures 4D-E).
Animal weight has been demonstrated to be an objec-
tive parameter for disease progression in SOD1G93A
mice [21] with continuing weight gain in the pre-symp-
tomatic phase (up to 13 weeks of age) and a denerva-
tion-induced weight loss in the symptomatic phase
(Figure 4F). The inflection point of the weight curve for
BDNF-TTC- and TTC-treated mice was delayed one
and two weeks, respectively, but BDNF-treated animals
did not differ from positive control SOD1G93A mice. In
addition, TTC treatment helped to maintain significantly
higher weights in SOD1G93A mice during 15 and 16
weeks of age, but BDNF-TTC treatment induced differ-
ences from 14 to 18 weeks of age, indicating a delay in
disease progression.
The beneficial effect of naked DNA (TTC, BDNF-TTC
and BDNF) treatment was also tested by an assessment
of motor function and coordination on the rotarod from
8 weeks of age through the end-stage (Figure 4G). The
rotarod performance during weeks 10 to 15 was signifi-
cantly improved in TTC- and BDNF-TTC-treated mice
compared to positive control SOD1G93A mice. The
latency on the rotarod began to decrease progressively
after 10 weeks of age in control SOD1G93A mice,
whereas the transgenic mice transfected with TTC or
BDNF-TTC plasmids showed a decrease of latency after
15 and 16 weeks of age, respectively. The overall rotarod
performance was slightly improved in BDNF-treated
mice, although no significant differences were observed
with respect to the positive control SOD1G93A mice
except for two time points (10 and 14 weeks of age).
Electrophysiological evaluation of the neuromuscular
function of SOD1G93A mice
The neuromuscular function of SOD1G93A mice was
assessed at 12 weeks, which is just before the time of
clinical onset, and 16 weeks of age, which is during a
late symptomatic stage. By 12 weeks of age, motor nerve
conduction tests already revealed marked abnormalities,
evidenced by a 40-60% decline in the amplitude and
about a 20% increase in the latency of the CMAPs in
the transgenic mice compared to age-matched wild-type
mice (Table 2). From 3 to 4 months, there was a further
marked reduction in the CMAP amplitudes in positive
control SOD1G93A mice to about 20-25% of normal
values in plantar muscles and to about 45% in gastro-
cnemius muscles (Figure 5). This decline was less pro-
nounced in BDNF-, TTC- and BDNF-TTC-treated mice
(to 55%-65% of normal values), although these differ-
ences did not attain significance. These results agree
with our previously published data that described in
vivo that TTC treatment not only delayed the disease
onset but also prolonged life span and improved coordi-
nation and motor/neuromuscular function [10].
Spinal motoneuronal loss in SOD1G93A mice
The extent of motoneuronal degeneration was deter-
mined by counting the number of cresyl stained moto-
neurons in the ventral horns of lumbar spinal cord
sections of SOD1G93A mice at 16 weeks of age. Figure 6A
shows representative spinal cord sections from wild-type,
positive control SOD1G93A mice and SOD1G93A mice
injected with pCMV-BDNF or pCMV-BDNF-TTC. The
number of surviving motoneurons that met the size and
shape criteria was significantly reduced in the lumbar
spinal cord in SOD1G93A mice compared to wild-type
age-matched controls. Nevertheless, the group treated
with BDNF-TTC showed a close to normal number of
surviving motoneurons in the L2 segment, which corre-
sponds to the quadriceps muscle motor nucleus, whereas
the group treated with TTC had only moderate improve-
ment. In sections corresponding to the L4 segment, the
number of motoneurons was similar between the 3 treat-
ment groups and was slightly higher than in the positive
control SOD1G93A mice (Figure 6B).
Effect of naked -DNA treatment on apoptotic and survival
pathways
After intramuscular injections of the different plasmid
constructions in SOD1G93A mice, the spinal cord was
analyzed at a late symptomatic stage to determine
whether these molecules activated anti-apoptotic and
survival pathways. The protein expression pattern of
procaspase-3, activated caspase-3, Bax and Bcl2 proteins
involved in apoptosis was studied. Mice treated with
pCMV-TTC, BDNF-TTC or BDNF showed significantly
lower levels of caspase-3 activation compared to the
positive control SOD1G93A mice. Caspase-3 activation
levels were close to the levels observed in the spinal
cords of wild-type age-matched mice, suggesting that
the abnormal apoptotic process in SOD1G93A mice was
reduced by TTC, BDNF and BDNF-TTC treatment.
Procaspase-3 protein levels were similar between the
positive control group and the TTC-treated group,
whereas mice treated with BDNF-TTC and BDNF
showed a significant decrease in procaspase-3 expression
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Figure 4 Effect of naked -DNA treatment on the course of disease in ALS transgenic SOD1G93A mice. A. Table of the onset of symptoms
and mortality of SOD1G93A transgenic mice treated with naked DNA TTC, BDNF-TTC, BDNF and empty-plasmid (positive control) (n = 10 mice
per group, balanced males and females). B. Cumulative probability of the onset of disease symptoms (hanging-wire test) and survival (D) in
SOD1G93A mice injected at 60 days of age with TTC, BDNF-TTC, BDNF or empty (positive control) plasmids. Bar graphs representing the average
age of disease onset (C) and life span (E). F. Weight measurements of transgenic mice treated with the different constructions. G Strength and
motor function were tested using the rotarod at 15 rpm. Mice were given up to 180 s for the test performance and the time at which mice fell
was recorded (*, #, +, P < 0.05; **, ##, P < 0.01; error bars indicate SEM); * for BDNF-TTC vs. positive control comparisons; # for TTC vs. control
comparisons; + for BDNF vs. positive control comparisons.
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patterns, approaching the levels of wild-type age-
matched animals (Figure 7A).
Bax and Bcl2 have also been implicated in the degen-
eration of motoneurons in SOD1G93A mice [32]. We
found a significant upregulation in the expression of the
pro-apoptotic protein Bax in the spinal cord of positive
control SOD1G93A mice relative to the wild-type age-
matched mice (negative control). However, Bax levels
approached normal levels in BDNF-TTC- and BDNF-
treated animals. TTC-treated mice showed a slight but
significant decrease in Bax expression compared to the
positive control group. Regarding the anti-apoptotic Bcl2
protein, positive control SOD1G93A mice had a significant
increase in expression, but the different treatments
caused a reduction in Bcl2 levels, indicating that these
treatments could be restoring the neurodegenerative pro-
cess by which Bcl2 expression is altered (Figure 7B).
Because BDNF and TTC have already been described to
be involved in the activation of 2 different survival signal-
ing pathways in vitro, such as the PI3K/Akt and MAPK/
ERK pathways [15], we investigated how treatment with
the different plasmid constructs could affect these
cascades in SOD1G93A mice by analyzing the phosphory-
lation state of Akt and extracellular signal-regulated
kinase (ERK) proteins in the spinal cord. We found that
phospho-Akt levels were significantly higher in TTC-,
BDNF-TTC- and BDNF-treated mice compared to posi-
tive control SOD1G93A mice. Interestingly, phospho-Akt
levels in all treated mice were similar to the levels of
phospho-Akt in wild-type age-matched mice (negative
control). However, phospho-ERK protein expression was
increased almost 4-fold in positive control SOD1G93A
mice compared to the wild-type age-matched animals. In
all treated animals, ERK activation levels were signifi-
cantly reduced compared to positive control SOD1G93A
mice (Figure 7C). The expression levels of baseline Akt
and ERK 1/2 kinases were also tested, and statistical sig-
nificance was found only in baseline ERK 1/2 levels
between the positive control group and the rest of groups
(i.e., the negative control and TTC-, BDNF-TTC- and
Table 2 Neurophysiological study in gastrocnemius and plantar muscles
Group (n) Gastrocnemius muscle Plantar muscle
Latency (ms) CMAP (mV) Latency (ms) CMAP (mV)
3 months
WT (6) 0.93 ± 0.04 51.9 ± 2.2 1.66 ± 0.08 6.49 ± 0.47
SOD control (6) 1.11 ± 0.05 27.8 ± 2.9* 2.00 ± 0.10 2.55 ± 0.57*
SOD BDNF (7) 1.12 ± 0.05 32.1 ± 5.0 1.89 ± 0.08 2.69 ± 0.44*
SOD TTC (6) 1.04 ± 0.02 28.6 ± 3.5 1.95 ± 0.07 3.10 ± 0.52*
SOD BDNF-TTC (8) 1.10 ± 0.05 32.1 ± 7.4 2.01 ± 0.11 2.64 ± 0.47*
4 months
WT (6) 0.93 ± 0.05 53.6 ± 4.2 1.59 ± 0.03 6.89 ± 0.79
SOD control (5) 1.09 ± 0.04 13.0 ± 2.6* 1.98 ± 0.03 0.89 ± 0.35*
SOD BDNF (5) 1.10 ± 0.06 18.1 ± 3.1* 1.88 ± 0.04 1.52 ± 0.41*
SOD TTC (5) 1.06 ± 0.03 18.7 ± 4.8* 2.03 ± 0.15* 1.91 ± 0.83*
SOD BDNF-TTC (5) 1.11 ± 0.07 20.9 ± 9.3* 2.02 ± 0.16* 1.68 ± 0.71*
Results of wild-type mice (WT), control SOD1G93A mice, and SOD1G93A mice treated with naked DNA encoding for BDNF, TTC, and BDNF-TTC are shown. Values
are the mean ± SEM. CMAP, compound muscle action potential; n, number of mice.
*P < 0.05 vs. WT group at the same age.
Figure 5 Histogram representation of the decrement in the
amplitude of the compound muscle action potential. CMAP was
compared at 4 months with respect to values at 3 months of age
in SOD1G93A mice, untreated and treated with naked DNA encoding
for BDNF, TTC or BDNF-TTC. For each group, the left bar
corresponds to the gastrocnemius muscle and the right bar to the
plantar muscle (n = 7 mice per group).
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Figure 6 Motor neuron survival in SOD1G93A mice. A. Representative micrographs showing cross-sections of lumbar spinal cords stained with
cresyl violet from wild-type, a, SOD1G93A control (positive control), b, BDNF-treated, c, and BDNF-TTC-treated, d, mice at 16 weeks of age. Bar =
500 μm. B. Histogram representation of the average number of stained motoneurons per section in L2 and L4 spinal cord segments of wild-type
littermates, control SOD1G93A and treated mice (n = 4-5 mice per group). * p < 0.05 vs. wild type; # p < 0.05 vs. SODG93A control mice.
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Figure 7 Western blot analysis of proteins involved in the apoptotic and survival signalling pathways. A. Fold-changes in the expression
of pro-Casp3 and active Casp3 proteins. B. Bax and Bcl2 proteins and (C) phosphorylated states of Akt and ERK1/2 proteins in spinal cord lysates
of control SOD1G93A animals (white) and animals treated with TTC (grey), BDNF-TTC (blue, BTTC) and BDNF (soft blue). Western blot quantities
are shown as the ratios to b-tubulin and then related to age-matched wild-type (black) mice data. Significant differences were found in all
treated groups compared to control SOD1G93A mice except for pro-Casp3 protein expression in TTC-treated mice. Biochemical behavior of
treated transgenic animals resembled that of wild-type age-matched mice (n = 5 mice per group). The normalization of total protein ERK1/2
expression levels as a ratio to b-tubulin yielded a significant increase in the control group (white) with respect to the rest of groups (wild type,
TTC-, BDNF- and BDNF-TTC-treated groups). The expression level of total protein of Akt and ERK 1/2 kinases was determined using the
housekeeping protein b-tubulin (*P < 0.05 and **P < 0.01 vs. control SOD1G93A mice; ***p < 0.001; error bars indicate SEM).
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BDNF-positive-treated groups) in accordance with our
previous results [22]. For this reason, Akt and ERK 1/2
phosphorylation levels were determined in relation to the
housekeeping protein b-tubulin. The expression levels of
both of the phosphorylated and baseline proteins in all of
the treated animals, but not in the positive control group,
showed a trend toward the normal levels of wild-type
animals. These results suggest that the variations in the
expression levels were due to the treatments.
Discussion
The recombinant BDNF-TTC and GDNF-TTC proteins
have shown a stronger effect than the TTC fragment
alone in inhibiting apoptosis in cultured neurons [9,12].
Recently, in vivo studies [10] confirmed the therapeutic
benefits of TTC in a murine model of motoneuron dis-
ease. Taking into consideration that the specificity of a
trophic factor for motoneurons could be increased by
genetically fusing it to TTC, while the trophic factor
could contribute to enhance the benefits observed for
TTC, our next approach was to test naked-DNA gene
delivery to encode for a chimeric molecule, BDNF-TTC,
in order to study the potential synergistic effect of these
molecules in one of the best characterized neurodegen-
erative animal models, the SOD1G93A mice.
Our results revealed that BDNF-TTC and TTC treat-
ments induced a significant improvement in survival
and motor function and a delay in the onset of symp-
toms and in the loss of body weight (Figure 4). Contrary
to what we expected, no significant differences were
found between the treatments. This fact suggests a lack
of synergistic effect in the BDNF-TTC molecule and
resembles other results with similar fusions [11], which
point TTC as the main beneficial component of the
fusion molecule. Therefore, we wondered whether the
effect of BDNF-TTC treatment was mainly due to TTC
because the recombinant plasmids were detected in ske-
letal muscle and their corresponding proteins reached
the spinal cord tissue (Figures 2, 3A). This implied that
BDNF in the fusion molecule was not active enough to
exert a synergistic effect with TTC. Although the neuro-
protective properties of other chimeric molecules, such
as GDNF-TTC, have also been tested and yielded posi-
tive results [12], the genetic fusion of trophic factors to
larger proteins could alter protein folding and confor-
mation, thereby undermining the neuroprotective prop-
erties [33]. However, other authors have suggested that
proteins coupled to TTC share its long-term stability
[34]. Nevertheless, to assure this fact, the gene expres-
sion of the GABA(A) receptor was studied in the spinal
cord tissue of all treated animals because the exposure
to BDNF induces a reduction in postsynaptic GABA(A)
receptor number in cultured neurons [35]. Our findings
showed a downregulation of the expression of a GABA
(A) receptor subunit in the spinal cord of BDNF- and
BDNF-TTC-treated mice, but not in TTC-treated and
control SOD1G93A mice (Figure 3B), which suggests that
BDNF influences GABA(A)-mediated transmission.
These results also suggest that TTC might not exert its
action at the inhibitory synaptic transmission level.
However, GABA(A) receptor down-regulation may be a
useful marker of the action of BDNF and can be used to
confirm the active state of BDNF in the recombinant
molecule.
The next step was to test whether the different effica-
cies of the injected molecules in reaching the spinal
cord tissue could yield different responses depending on
the treatment. To conduct this study, we tested motor
and neuromuscular functions and motoneuronal survival
in the treated mice and investigated the molecular path-
ways involved in the pathogenesis of ALS.
Despite being non-significant, we detected a reduction
in the decline of CMAPs amplitude in all the treated
animals compared to the control SOD1G93A mice
(Figure 5) and a higher number of motoneurons in L2
and L4 spinal cord segments in the treated animals than
in the control SOD1G93A mice. At L2, BDNF-TTC trea-
ted animals showed the highest number of surviving
motoneurons, being higher than in TTC-treated ani-
mals, and close to the numbers of motoneurons in wild-
type mice (Figure 6).
The main question that arises from these results is why
this significant preservation of spinal motoneurons under
BDNF-TTC treatment did not yield a significant
response compared to TTC treatment in the survival and
behavioral tests. One explanation could be the possible
autocrine modulation of BDNF as observed in SOD1G93A
mice under iron-chelating drug treatment [36]. Similarly,
because we confirmed the active state of BDNF in the
recombinant molecule, this BDNF could activate survival
pathways that promote the production of more BDNF
through the activation of Akt and ERK [15].
An increase of phospho-Akt levels was found in treated
animals compared to positive control SOD1G93A mice
and was similar to the expression level profiles under all
of the treatments (Figure 7C). Although all of the treated
groups showed lower levels of phospho-ERK than the
positive control SOD1G93A mice, which indicated a sig-
nificant amelioration of motoneuronal degeneration in
these animals, the highest phospho-ERK levels were
detected with BDNF-TTC treatment (Figure 7C),
suggesting that BDNF in the fusion molecule more effi-
ciently reached the spinal cord where it may have exerted
its autocrine effect. In fact, the TTC fragment contains a
non-identified secretion signal peptide and, in the present
study, we fused TTC to the mature form of BDNF that
lacked its own signal peptide. Therefore, the fusion pro-
tein secretion must have followed the TTC secretion
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pathway, and this was confirmed by Western blot and by
the immunohistochemical detection of BDNF in spinal
cord samples of BDNF-TTC-treated mice (Figures 2B, 3A).
Nevertheless, this BDNF-enhanced production through
phospho-ERK activation was not enough to prompt a
synergistic effect of the chimeric molecule.
The analysis of programmed cell death markers has
provided evidence to suggest the implication of apopto-
tic pathways in ALS patients and in mouse models of
the disease [37]. Our results showed a tendency to nor-
malize the function of these pathways under all of the
treatments administered. In particular, TTC, BDNF-
TTC and BDNF treatments inhibited apoptotic path-
ways in the spinal cord of SOD1G93A mice by reducing
the activation of pro-caspase 3 and active caspase-3 and
by reducing Bax and Bcl2 protein levels close to levels
observed in wild-type mice (Figures 7A-B). Contrary to
previous observations [32], Bcl2 over-expression was
found in positive control SOD1G93A mice. This might be
due to a reactive up-regulation of Bcl2 expression
because mutant SOD1 proteins bind and aggregate with
Bcl2 in the spinal cord [38].
These results are in accordance with the well-known
potential of BDNF to enhance the survival of motoneur-
ons in culture and in in vivo models of degeneration
[39], presumably through the activation of anti-apoptotic
signals, and with the neuroprotective effects of TTC
demonstrated in vitro and in vivo, including the preven-
tion of the stress-induced death of cultured neurons and
the activation of survival signaling pathways [9,10,15,40].
Interestingly, BDNF-TTC-treated animals showed a
similar protein expression pattern to TTC-treated ani-
mals, especially of active caspase-3 levels. This suggests
that TTC exploits a non-classical secretion pathway that
mimics a neurotrophic secretion pathway but uses
another route that might be important for the survival
of motoneurons and prompting different biochemical
activations in the spinal cord of SOD1G93A mice. There-
fore, BDNF-TTC, unlike BDNF alone, could also use the
same pathway as TTC to induce a similar effect.
In summary, the first link in the destabilization chain
of motor nerve terminals and the subsequent dying back
of the axons and motoneurons remains unknown in
ALS. The fact that TTC and BDNF-TTC can be trans-
ported through motoneurons to induce a later onset of
symptoms, improve motoneuron survival and extend the
survival of SOD1G93A mice suggests that the naked
DNA-mediated intramuscular delivery of TTC and
BDNF-TTC fusion molecules promotes neuroprotective
effects in the SOD1G93A murine model of ALS. Never-
theless, our results suggest that this neuroprotective
effect may be mainly due to TTC in the case of the
fusion molecule, despite the active state of the trophic
factor, and for this reason, testing the effects of TTC
alone is a necessary step to tackle the potential effects
of any fusion molecule based on TTC.
Conclusions
We have studied the potential synergistic effect of the
fusion molecule BDNF-TTC in SOD1G93A mice, one of
the best-characterized neurodegenerative animal models
for ALS. Despite observing a significant improvement in
behavioral, electrophysiological and immunohistochem-
ical assays together with an activation of anti-apoptotic
and survival pathways under BDNF-TTC treatment, no
synergistic effect was found using the BDNF-TTC mole-
cule. Moreover, the detection of BDNF-TTC in the
spinal cord of SOD1G93A-treated mice and the active
state of BDNF in the fusion molecule suggest that
BDNF could exert an autocrine and neuroprotective
role together with TTC to a similar extent as TTC
alone, but this effect was not sufficient to enhance the
survival signals observed under TTC treatment alone.
A better understanding of the neuroprotective effects of
the TTC fusion molecules needs to be studied carefully
because the observed effects might be mainly due to
TTC itself.
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